NORML

JUNE 1, 2020

On Sunday, legislators finalized HB 819 , which expands the discretion of physicians so that they can recommend cannabis therapy for “any condition” that he or she “considers debilitating to an individual patient and is qualified through his [or her] medical education and training to treat.” John Bel Edwards.

Access 215

Access Therapy Legislation Patients 215

Cannabis Law Report

JUNE 16, 2021

This relationship enables us to initiate our clinical research program and marks an important step for Wake in Canada. We are excited to explore the potential of emergent psychedelic therapies. Santé Cannabis is a leading medical clinic and research centre dedicated to medical cannabis treatments and complementary medicines.

Clinical Trials 104

Clinical Trials Therapy Research and Development Events 104

Veriheal

JULY 18, 2023

The Grant Program Details The heart of this landmark legislation lies in the development of a robust grant program. Notably, the grant program will target three prevalent and often debilitating conditions in military personnel: PTSD, traumatic brain injury (TBI) , and chronic traumatic encephalopathy (CTE).

Treatment 98

Treatment Clinical Trials Research and Development Legislation 98

Cannabis Law Report

MAY 19, 2022

This is Numinus’ first psilocybin-assisted therapy treatment outside of ongoing clinical trials, and among the first to use of this regulatory mechanism through Health Canada’s Special Access Program (“SAP”), which was amended January 5 th , 2022 to include access to psychedelic compounds on a case-by-case basis.

Therapy 52

Therapy Treatment Clinical Trials Access 52

NORML

FEBRUARY 5, 2019

It’s vital that we speak as one voice for a medical program.” Jason Nemes, R-33, is sponsoring a medical cannabis bill (HB 136) that allows doctors to recommend cannabis therapy as part of patients’ treatment regimens. KY4MM has been extremely important in helping to get all of our supporters to come together.

Decriminalization 212

Decriminalization Legislation Treatment Therapy 212

Medical Marijuana Pages

JUNE 10, 2024

In a groundbreaking decision, Connecticut Expands Medical Marijuana Program to Include Autism (ASD). To its list of qualifying conditions for the state’s medical marijuana program. This significant development opens new avenues for treatment. The inclusion of autism.

Programs 70

Programs Therapy Marijuana Treatment 70

Veriheal

JANUARY 9, 2024

Their newest bipartisan bill will push this agenda by creating a framework for mental health providers to offer psilocybin-assisted therapy to military veterans and first responders battling mental illnesses like post-traumatic stress disorder (PTSD), anxiety, depression, and more.

Therapy 64

Therapy Legalization Treatment Decriminalization 64

Puff Puff Post

DECEMBER 28, 2018

We go deep into what this might mean for the future of therapy for Autism Spectrum Disorders (ASD), and how we might see the use of CBD oil for autism. Success rates of up to 80% have been observed for CBD related autism therapy. The Current Treatments for Autism. CBD Oil For Autism: Highlights. What Exactly is Autism ?

Treatment 76

Treatment Oil CBD Therapy 76

Cannabis Law Report

MAY 4, 2022

Connecticut lawmakers sent the governor a large-scale budget bill on Tuesday that includes provisions to set the state up to provide certain patients with access to psychedelic-assisted treatment using substances like MDMA and psilocybin. Connecticut Lawmakers Send Psychedelic Treatment Program Proposal To Governor As Part Of Budget Bill.

Treatment 52

Treatment Programs Therapy Access 52

Veriheal

JUNE 29, 2021

In the last 100 years, many of the plant therapies that were embraced in history were outlawed by governments around the world and replaced by lab-made synthetic drugs we label medicine. The FDA refers to this program as the expanded access program on their website. Cannabinoid Therapies for Cancer Patients.

Therapy 64

Therapy DEA Patients Clinical Trials 64

NORML

FEBRUARY 23, 2020

Legislation is pending, Senate Bill 165, to establish a medical marijuana access program for qualified patients with a physician’s recommendation to access medical marijuana from licensed retail outlets. The bill would allow qualifying patients to access all the alternative treatment centers instead of having to designate just one.

Legislation 253

Legislation Patients Decriminalization Access 253

The Joint Blog

JUNE 15, 2020

The study is titled Will medical cannabis treatment reduce pharmaceutical residues in the aquatic environment? According to NORML participants in the study were enrolled in Israel’s federal marijuana access program and were able to choose from four select strains of cannabis.

Therapy 59

Therapy Environment Pharmaceutical Consumption 59

MMJ Recs

AUGUST 16, 2024

Traditional treatments include eye drops, oral medications, laser treatment, and surgery. However, there has been growing interest in alternative therapies, including medical marijuana to treat glaucoma. However, the need for frequent dosing and potential side effects make it less practical as a primary treatment option.

Treatment 111

Treatment Marijuana THC Strains 111

Cannabis Law Report

MARCH 29, 2023

. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it has launched the Numinus Certification Pathway – a collection of psychedelic-assisted therapy (“PAT”) training courses (..)

Therapy 52

Therapy Programs Collective Treatment 52

Cannabis Law Report

JUNE 23, 2021

In addition to the pilot program, the parties are working toward an exclusive, definitive supply and distribution agreement, which, if entered into, is expected to position Medicann as the sole supplier and distributor of the RYAH Smart Dry Herb Inhalers in the region. to reach 3.2 billion euros ($3.75 billion) by 2025. 310.299.1717 Office.

Programs 100

Programs Data Events Collective 100

Cannabis Law Report

JULY 29, 2021

These assets include 5 addiction treatment clinics across the province of Alberta that have conducted over 35,000 patient visits during the past 12 months. Each clinic employs a highly educated and specialized team of dedicated physicians, nurses and therapists working in unison with patients to ensure treatment goals are achieved.

Chronic Pain 105

Chronic Pain Treatment Therapy Patients 105

Kind Meds (Cannabis Education Blog)

AUGUST 24, 2018

As a part of the Arizona Medical Marijuana Act, Marijuana in Arizona can be used to treat: “A chronic or debilitating disease, medical condition or the treatment that causes: Cachexia or wasting syndrome. States with Medical Marijuana Programs Fill Less Opioid Prescriptions. Marijuana as a Treatment for Opioid Addiction in Arizona?

Chronic Pain 99

Chronic Pain Marijuana Therapy Treatment 99

Project CBD

SEPTEMBER 12, 2023

But the quality of the government-issue reefer matters less than the fact that Uncle Sam has been supplying him with it regularly since 1982, when Rosenfeld won the right to smoke cannabis for reasons of medical necessity under the auspices of the federal government’s Compassionate Investigational New Drug (IND) program. 2012.06.022.

Chronic Pain 236

Chronic Pain Treatment Research and Development Cannabinoids 236

MMJ Recs

JULY 9, 2024

Traditional treatments, while helpful to some extent, often come with limitations and side effects that can further burden individuals already dealing with a debilitating disease. Medical marijuana has emerged as a promising alternative treatment option for managing symptoms associated with MS.

Marijuana 111

Marijuana Treatment Cannabinoids Patients 111

Cannabis Law Report

MAY 19, 2022

When Thomas Hartle indulges in a session of psilocybin treatment, the end-of-life anxiety, distractions and noises associated with his terminal colon cancer go away. “Before the treatment, it’s like you’re sitting in your car. There must have been a lot of treatments done beforehand so the application is solid.”

Therapy 52

Therapy Patients Treatment Clinical Trials 52

MMJ Recs

NOVEMBER 17, 2023

By legalizing MMJ, the state has facilitated access to a natural and potentially life-changing treatment option for patients suffering from various medical conditions. Support for Patient Well-Being The availability of medical marijuana in local communities fosters an environment of support for patients seeking alternative treatments.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Cannabis Law Report

FEBRUARY 24, 2022

Canada recently amended its Controlled Drugs and Substances Act (CDSA) to allow for psilocybin and MDMA therapy in limited circumstances. Subsection 56(1) of the CDSA will exempt medical providers from enforcement of the CDSA when providing psilocybin and MDMA treatment to patients suffering serious or terminal health conditions.

Therapy 52

Therapy Access Clinical Trials Treatment 52

Veriheal

JANUARY 18, 2024

Cannabis nurses are crucial in bridging the gap between traditional healthcare and emerging cannabis therapies. These nurses also offer valuable insights on integrating cannabis therapies into various healthcare settings, including dispensaries, primary care clinics, and specialized pain management centers. So what does it all mean?

Education 116

Education Therapy Patients Research and Development 116

Cannabis Law Report

JUNE 23, 2021

The company has plans to open three UK psychedelic-assisted psychotherapy clinics where it will deliver ketamine-assisted therapies near term and MDMA when they secure authorization in 2021 (Bristol, London, and Manchester). The company’s target is 20 clinics by the end of 2024. by Toronto-based Awakn Life Sciences Inc.

Clinical Trials 85

Clinical Trials Therapy Research and Development Treatment 85

Cannabis Law Report

SEPTEMBER 10, 2021

is a pioneering Psychedelic Healthcare Innovation & Life Sciences Company in early stage development of Psilocybin (“Magic Mushroom”) based drugs and therapies proudly announces t he Filing of U. HENDERSON, Nev. , Sept. 9, 2021 /PRNewswire/ — PsiloThera, Inc.

Microdosing 98

Microdosing Research and Development Therapy Treatment 98

Cannabis Law Report

OCTOBER 20, 2021

International Summit on Psychedelic Therapies for Mental Illness 17-20 November 2021. The event will also feature a two-day pre-Summit Introductory Workshop Program (17-18 November) led by Nigel Denning, Dr Tra-ill Dowie with world-leading therapist trainer Dr Bill Richards (USA) from Johns Hopkins University.

Therapy 52

Therapy Medicine Topical Events 52

Cannabis Law Report

SEPTEMBER 10, 2021

This exciting partnership between these innovative startups aims to advance patient access to psychedelic treatments in Europe, and improve the quality of the psychedelic medicines produced in Europe. We look forward to working closely with the Clerkenwell Health team to advance our psychedelic drug programs through clinical trials.”.

Research and Development 104

Research and Development Clinical Trials Therapy Environment 104

Cannabis Law Report

JULY 13, 2022

Physicians and researchers are urging New Mexico legislators to allow the use of psychedelic mushrooms in mental health therapy aimed at overcoming depression, anxiety, psychological trauma and alcoholism. Oregon is so far the only state to legalize the therapeutic use of psilocybin.

Therapy 52

Therapy Legislation Access Decriminalization 52

Veriheal

JULY 2, 2020

Louisiana has had a medical cannabis program for many years. In late May, Louisiana lawmakers discussed a bill that would significantly expand the state’s medical cannabis program and offer access to thousands of more patients in the state that may benefit from cannabinoid therapies. The Bill as Passed.

Banking 52

Banking Programs Therapy Conditions 52

Cannabis Law Report

OCTOBER 22, 2021

(TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a neuropharmaceutical company focused on psychedelic-assisted therapies, is pleased to announce that following discussions with the U.K. The ILAP accelerates time to market and facilitates patient access to emerging and novel treatments. About Small Pharma.

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

NORML

MARCH 7, 2020

The measure would permit physicians to recommend cannabis therapy to those diagnosed with an autism spectrum disorder as well as opioid use disorder. House Bill 330 adds chronic pain associated with fibromyalgia to the set of conditions qualifying a patient for treatment with medical marijuana. LA resident? NH resident?

Legislation 252

Legislation Decriminalization Patients THC 252

Project CBD

FEBRUARY 1, 2023

Anyone who has paid any attention to the cannabis “wellness” industry in recent years — whether through state medical and recreational programs or the free-for-all national CBD market — will be familiar with cannabinoid-infused topicals marketed to treat minor aches and pains. Suffice to say, they are thorough.

Conditions 130

Conditions THC CBD Cannabinoids 130

Cannabis Law Report

DECEMBER 14, 2021

Assemblyman Pat Burke (D) filed the legislation, which would create a system in New York that’s similar to the psilocybin program that was legalized via a ballot initiative in Oregon last year.

Treatment 52

Treatment Legalization Therapy Environment 52

Cannabis Law Report

JANUARY 26, 2022

MDMA as an adjunct to therapy for PTSD is the forty-first treatment to receive the Innovation Passport since its inception in January 2021. The Innovative Licensing and Access Pathway (ILAP) Innovation Passport has ben granted to MDMA as an adjunct to therapy for posttraumatic stress disorder (PTSD) in the United Kingdom (UK).

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

Cannabis Law Report

JUNE 18, 2021

Atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. ATAI expects to initiate a Phase 2 trial for another program in 2021 and an additional three Phase 2 trials for other programs in 2022. Its most famous investor is Peter Thiel.

Treatment 89

Treatment Therapy Programs Conditions 89

Canna Law Blog

FEBRUARY 19, 2020

They certainly do not yet resemble the second wave of “retail model” programs that became standard with medical and adult use cannabis. This type of proposal envisions psilocybin-assisted therapy in controlled environments. These initiatives do not contemplate a commercial model and it seems unlikely that they will be lucrative.

Decriminalization 133

Decriminalization Research and Development Therapy Pharmaceutical 133

Cannabis Law Report

JUNE 12, 2021

The Parker Psychedelic Research Chair is being funded by Calgary businessman Jim Parker, who donated $3 million to the Hotchkiss Brain Institute to establish the program. She says the treatment did little but left her feeling numb and unable to heal. The treatments were carefully dosed and conducted under medical supervision.

Therapy 81

Therapy Treatment Medicine Sleep 81